Diabetes Mellitus, Type 2DESCENDANCENCT05567692
Subjects With T2D or at Risk of T2D Cohort Follow-up
An observational study of Diabetes Mellitus, Type 2, run by Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète at 1 site in France.
Trial summary
The main objective of this study is to prospectively follow the subjects included in "Descendance" cohort and to describe the occurrence of type 2 diabetes in non-diabetic subjects, which will allow us to iteratively update the "Descendance" Type 2 Diabetes risk prediction model. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- OGTT, HbA1c and Questionnaire
- Type of treatment
- Pill or oral medicine
- How many people
- 837 participants
- Where
- 1 siteFrance
- Study dates
- 10 Feb 2023to 1 Oct 2032
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All subjects included in the DESCENDANCE clinical trial (Id: NCT01727349) between 20011 and 2020, will be re-invited to participate in the Descendance cohort follow-up.
Who may be able to join
- Subjects have participated in the Descendance study
- Subjets who sign informed consent to participate in the study
Who cannot join
- Subjects not enrolled in Descendance study
- Subjects refusing to participate
- Pregnant or breastfeeding
- Subjects in emergency situations, under legal protection or unable to provide informed -consent
- Subjects lost to follow-up or died
Trial locations and contacts
1 site in 1 country.
France1 site
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Évry, 91058
About this study
Official title: Descendance Cohort: Follow-up of Subjects With Type 2 Diabetes or at Risk of Type 2 Diabetes Defined by the Existence of the Disease in the Family in Two Successive Generations
The main objective of this study is to prospectively follow the subjects included in "Descendance" cohort and to describe the occurrence of type 2 diabetes in non-diabetic subjects, which will allow us to iteratively update the "Descendance" Type 2 Diabetes risk prediction model.
Read the detailed description
High risk families will be prospectively follow in order to better understand the risk of transmission of type 2 diabetes from one generation to another. The cohort will also allow us to collect additional data on diabetic patients.
The monitoring of the cohort will take place for at least 10 years with a follow-up of all participants every three years. To detect individuals who develop dysglycemia during the study, a glucose tolerance test (GTT) and HbA1c measurement will be conducted.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- OGTT, HbA1c, Questionnaire
- Keywords
- Type 2 diabetes ; Risk Prediction ; Prevention
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OGTTDiagnostic test
Oral Glucose Tolerance Test
HbA1cOther
HbA1c measurement
QuestionnaireOther
Follow-up questionnaire
| Study group | Role | What they receive |
|---|---|---|
| T2D group | subjects with type 2 diabetes Receives: Other: Questionnaire | |
| Non-T2D group | healthy subjects Receives: Diagnostic Test: OGTT; Other: HbA1c; Other: Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Type 2 diabetes incidence in Descendance population
Presence of type 2 diabetes mellitus, on basis of self-reported (physician diagnosis) or diagnosed by OGTT and HbA1c
Measured: 9years
Secondary outcomes (2)
Provide estimates of prevalence of diabetes and prediabetes in Descendance population
To estimate the prevalence of undiagnosed diabetes mellitus and pre-diabetes in Descendance population
Measured: at baseline, 3-, 6- and 9-years follow-up
Study of interactions between risk factors on type 2 diabetes incidence
Self-administered questionnaire. "Descendance" specific questionnaire
Measured: at baseline, 3-, 6- and 9-years follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2022
- Study start10 Feb 2023
- Primary completion1 Oct 2032 (estimated)
- Study completion1 Oct 2032 (estimated)
Why it stopped: The sponsor has temporarily suspended study due to operational constraints.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 837 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
- Sponsor type
- University, hospital or other
- Collaborators
- Institut Pasteur de Lille
- Responsible party
- Sponsor
- Investigators
- Guillaume CHARPENTIER, Dr, Principal investigator, Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05567692
- Sponsor's protocol ID
- 2022-A01538-35
- Acronym
- DESCENDANCE
- Status last verified
- Apr 2026
- First submitted
- 22 Sep 2022
- Last updated
- 15 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Descendance Cohort: Follow-up of Subjects With Type 2 Diabetes or at Risk of Type 2 Diabetes Defined by the Existence of the Disease in the Family in Two Successive Generations
- ClinicalTrials.gov ID
- NCT05567692
- Acronym / sponsor ID
- DESCENDANCE / 2022-A01538-35
- Conditions
- Diabetes Mellitus, Type 2
- Keywords
- Type 2 diabetes ; Risk Prediction ; Prevention
- Study type
- Observational
- Recruitment status
- SuspendedReason stopped: The sponsor has temporarily suspended study due to operational constraints.
- Enrolment
- 837 participants (estimated)
- Lead sponsor
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du DiabèteUniversity, hospital or other
- Collaborators
- Institut Pasteur de Lille
- Study start
- 10 Feb 2023 (actual)
- Primary completion
- 1 Oct 2032 (estimated)
- Study completion
- 1 Oct 2032 (estimated)
- First posted
- 5 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this study is to prospectively follow the subjects included in "Descendance" cohort and to describe the occurrence of type 2 diabetes in non-diabetic subjects, which will allow us to iteratively update the "Descendance" Type 2 Diabetes risk prediction model.
Detailed description
High risk families will be prospectively follow in order to better understand the risk of transmission of type 2 diabetes from one generation to another. The cohort will also allow us to collect additional data on diabetic patients.
The monitoring of the cohort will take place for at least 10 years with a follow-up of all participants every three years. To detect individuals who develop dysglycemia during the study, a glucose tolerance test (GTT) and HbA1c measurement will be conducted.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| T2D group | – | Other: Questionnairesubjects with type 2 diabetes |
| Non-T2D group | – | Diagnostic Test: OGTT, Other: HbA1c, Other: Questionnairehealthy subjects |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All subjects included in the DESCENDANCE clinical trial (Id: NCT01727349) between 20011 and 2020, will be re-invited to participate in the Descendance cohort follow-up.
Key inclusion criteria (2 listed)
- Subjects have participated in the Descendance study
- Subjets who sign informed consent to participate in the study
Key exclusion criteria (5 listed)
- Subjects not enrolled in Descendance study
- Subjects refusing to participate
- Pregnant or breastfeeding
- Subjects in emergency situations, under legal protection or unable to provide informed -consent
- Subjects lost to follow-up or died
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OGTTOral Glucose Tolerance Test | Diagnostic test | Non-T2D group |
| HbA1cHbA1c measurement | Other | Non-T2D group |
| QuestionnaireFollow-up questionnaire | Other | Non-T2D group, T2D group |
Primary outcome
Type 2 diabetes incidence in Descendance population
Time frame: 9years
Presence of type 2 diabetes mellitus, on basis of self-reported (physician diagnosis) or diagnosed by OGTT and HbA1c
2 secondary outcomes
Provide estimates of prevalence of diabetes and prediabetes in Descendance population
Time frame: at baseline, 3-, 6- and 9-years follow-up
Study of interactions between risk factors on type 2 diabetes incidence
Time frame: at baseline, 3-, 6- and 9-years follow-up
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2026.
- Individual participant dataSharing planned: No
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Guillaume CHARPENTIER, Dr principal investigator
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes Mellitus, Type 2, run by Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Type 2 diabetes incidence in Descendance population (time frame: 9years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.